Supriya Lifescience Ltd
SUPRIYASupriya Lifescience Ltd's price has outrun its earnings. +39.2% in a year against EPS +11.3% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +39.2% in a year while annual EPS moved +11.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (15 weeks in) while the P/E sits at the 94th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −31.4% year on year, and 90% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Supriya Lifescience Ltd trades at ₹902, in a confirmed uptrend and 15 weeks into that stage. That is +15.0% against its own 200-day average. It sits at 75% of a 52-week range of ₹577 to ₹1,009. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (9 weeks and counting).
Today the stock is in a confirmed uptrend — week 15 of stage 2, confirmed. At ₹902 it trades +15.0% versus its 200-day average and sits at 75% of its 52-week range (₹577–₹1,009).
Against the market, two honest reads. Cumulative: over the last 4.7 years the stock moved +86% while the NIFTY 500 moved +49% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Supriya Lifescience Ltd's story is not scored yet against the markers our research file set on 27 June 2026. Where it sits in its own cycle: AT_PEAK. Our fortnightly research layers last read it on 27 June 2026.
Our read, 27 June 2026. A heavily backward-integrated API maker with a clean US FDA track record pivoting towards CDMO, but the near-peak multiples price in the near-term execution.
From the numbers. PE is at the top of its historical range, and normalized PE is also near peak. Margins are mid-cycle, confirming the stock is fairly priced for execution.
From the price. Price stage 2, week 15 — above its 200-day line, relative strength rising.
From the research. A heavily backward-integrated API maker with a clean US FDA track record pivoting towards CDMO, but the near-peak multiples price in the near-term execution.
🚨 Where they disagree. PE is at the top of its historical range, and normalized PE is also near peak. Margins are mid-cycle, confirming the stock is fairly priced for execution.
What is proven. A heavily backward-integrated API maker with a clean US FDA track record pivoting towards CDMO, but the near-peak multiples price in the near-term execution.
What is not proven yet. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.
🚨 What would change our mind. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.
Layer 1 read, 27 June 2026 — KEEP. Real API earnings inflection in Q4, but a top-decile PE and a string of deferred-launch promises hold it to P2. Supriya's March 2026 quarter jumped to 277cr revenue and 9.22 EPS from 6.17 a quarter earlier, and the jump is operational, not a one-off — other income was just 3cr and there were no exceptional items. The story is fuelled by the China-Plus-One API ramp and Ambernath coming on stream. But the stock trades at 35.7x earnings near the top of its own range with no margin of safety, and management has now pushed back its contrast-media, whey-protein and cardiovascular timelines three calls in a row.
What would change Layer 1’s mind. A Sep 2026 (Q2 FY27) quarter below 225cr revenue implying sub-20% annual pace, combined with another deferral of the cardiovascular 300 MT ramp or Ambernath EU audit — that would turn the repeated guidance slippage from tactical into structural and make the 35x PE unsupportable.
Layer 2 read, 27 June 2026 — BENCH. Real China+1 earnings inflection, but extended (5x run, 89th-pctile PE) into a sector flooding with capex — wait, BENCH. Supriya's Q4 FY26 PAT jumped 48% YoY on a clean operational quarter (zero exceptional, other_income just 3) and the API sector is in a genuine, broad, earnings-led expansion. But the price has already run 5.09x over 36-48 months and the PE sits at the 88.9th percentile [C001 — a model/⚠ percentile, treated as judged context], while the capital cycle reads CAPACITY_RISK — sector-wide capex flooding +33.5% with institutions absent — a forward supply headwind on an extended name. Management's guidance-delivery gap (contrast media, whey protein, cardiovascular all deferred) raises the bar for trusting the FY27 Rs 1,000cr target.
What would change Layer 2’s mind. An FY27 Q1 (Sep-2026 quarter) print at/above Rs 225cr revenue WITH the cardiovascular 300 MT and Ambernath EU-audit timelines reconfirmed-not-deferred — i.e. the guidance-delivery gap closing rather than widening (per the timeline's own would_change_my_mind) AND capex absorption visible (debtor days reverting, OCF/PAT lifting toward 1.0) — would flip BENCH→ADVANCE. Conversely a US FDA warning letter on any constituent (the sector verdict's named falsification) would push toward DROP.
The test written in advance. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. — the thesis as written as stated by the next result.
The test written in advance. Regulatory Audit Delays (Ambernath) — Regulatory Audit Delays (Ambernath) EU audit scheduling confirmation in Q2/Q3 FY27 calls by the next result.
The test written in advance. Valuation limits margin of safety — Valuation limits margin of safety Q2 FY27 revenue growth post-shutdown by the next result.
What the company does. FY26 revenue hit record highs with OPM steady, proving their ability to pass through raw material cost spikes. Regulatory hurdles cleared with a VAI for the Lote facility, and new capex is planned for Patalganga to support the revenue target. While the pipeline is robust with multiple launches per year and CDMO contracts ramping, the stock's valuation leaves little room for execution missteps.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| CDMO and DSM Partnership Ramp | HIGH | — | DSM contract scaling to a higher peak, with new liquid anesthetic CMO contracts in advanced stages. | The liquid anesthetic CMO term sheet falls through or is delayed beyond FY27. |
| Capacity Expansion (Patalganga & Ambernath) | MEDIUM_HIGH | — | Phase-one capex at Patalganga and Ambernath semi-regulated commercialization unlocks new volume growth. | A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent… |
| Backward Integration & Pricing Power | MEDIUM | — | Achieved high backward integration, protecting margins despite solvent price spikes. | A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent… |
🚨 What the surface reading misses. The surface reading is: trailing PE in the 92th percentile The research reads it further: normalized PE 94th %ile (Δ-2 pts); margins near mid-cycle (OPM 50th %ile) — surface and normalized readings agree.
Lever 6 · Order-book wins — BUILDING. DSM contract scaling to a higher peak, with new liquid anesthetic CMO contracts in advanced stages. What proves it keeps working: CDMO and DSM Partnership Ramp. It stops working if The liquid anesthetic CMO term sheet falls through or is delayed beyond FY27.
Lever 1 · Operating leverage — BUILDING. Phase-one capex at Patalganga and Ambernath semi-regulated commercialization unlocks new volume growth. What proves it keeps working: Capacity Expansion (Patalganga & Ambernath). It stops working if A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.
Lever 2 · Value-added mix — BUILDING. Achieved high backward integration, protecting margins despite solvent price spikes. What proves it keeps working: Backward Integration & Pricing Power. It stops working if A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.
Sources: our stock research file (27 June 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Supriya Lifescience Ltd reported ₹190 Cr of revenue in the Jun 26 quarter, +31.0% year on year. That is the 4th straight quarter of year-on-year growth. Over 9 years it has compounded at 18.2% a year. The last full year, FY26, came in at ₹828 Cr. The last four reported quarters add to ₹873 Cr.
Why this happened. The pivot to CDMO is materializing. With DSM volumes stabilized and liquid anesthetic CMO contracts in advanced term-sheet negotiations, this diversifies revenue away from pure API sales.
FY26 revenue came in at ₹828 Cr (+19.0% on the year), capping 9 years at 18.2% compound. The latest quarter (Jun 26) printed ₹190 Cr, +31.0% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +28.2% growth against the decade's 18.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +28.2% over the last 4 quarters against +20.7%/yr over the last 8 — accelerating; TTM profit +11.2% vs +20.7%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Supriya Lifescience Ltd's operating margin is 25.0% in the Jun 26 quarter, −11.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0% to 44.0%. The current quarter sits inside that band.
Why this happened. Capacity constraints are being addressed. Patalganga groundbreaking and the F-block Lote extension provide the runway for the revenue target and beyond.
The latest quarter's operating margin is 25.0%, −11.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0%–44.0%.
🚨 Why the margin moved: operating margin went −10.6 pp year on year while gross margin went −7.8 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Supriya Lifescience Ltd earned ₹24.0 Cr of net profit in the Jun 26 quarter, −31.4% year on year. Full-year FY26 profit was ₹209 Cr. The 9-year compound rate is 48.4%. That is 12.6% of the quarter's revenue. The same quarter a year earlier earned ₹35.0 Cr.
Jun 26 profit was ₹24.0 Cr, −31.4% year on year. On the full year, FY26 printed ₹209 Cr (+11.2%), and the 9-year compound rate is 48.4%.
🚨 Why profit moved: revenue contributed +31.0% and the margin −11.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +7.9% vs revenue +28.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 90% of Supriya Lifescience Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹186 Cr of operating cash against ₹209 Cr of profit. After ₹152 Cr of capital spending, ₹34.0 Cr was left as free cash.
FY26: operating cash of ₹186 Cr against reported profit of ₹209 Cr, leaving free cash of ₹34.0 Cr after ₹152 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 90% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 90%: the cash cycle stretched 37 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 7.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Supriya Lifescience Ltd's cash conversion cycle runs 167 days in FY26, up from 130 days in FY21. Capital spending ran ₹459 Cr over the last 3 years. At FY26 sales of ₹828 Cr each day of that cycle holds about ₹2.3 Cr, so roughly ₹379 Cr sits inside the business at any moment.
FY26: debtors at 97 days, inventory at 229 days — roughly 7.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 167 days, looser than FY21's 130.
The full loop: cash goes out to suppliers and production on day 0; stock waits 229 days to sell; customers pay about 97 days after that; and suppliers themselves are paid at 159 days — netting out to the 167-day cycle.
In money terms: at FY26 sales of ₹828 Cr, each day of the cycle holds about ₹2.3 Cr — so the 167-day loop keeps roughly ₹379 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹459 Cr over the last 3 fiscal years against ₹64.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹36.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Supriya Lifescience Ltd earns a ROCE of 25% in FY26. That is up from a trough of 14% in FY18. Return on invested capital clears the cost of that capital by +5.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 25.2% net margin on 0.61× asset turns.
FY26 ROCE is 25%, recovered from a FY18 trough of 14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 25.2% net margin × 0.61× asset turns × 1.13× balance-sheet leverage ≈ 17.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 17.0% − 12.0% = a +5.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Supriya Lifescience Ltd carries total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 1.2 points of Supriya Lifescience Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 6.2% of the company. Domestic institutions moved −0.2 points over the same window, to 5.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +1.2 points over 8 quarters to 6.2%; Domestic institutions: −0.2 points over 8 quarters to 5.3%; Promoters: +0.0 points over 8 quarters to 68.3%.
Why the register moved: foreign institutions drove it (+1.2 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Supriya Lifescience Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Supriya Lifescience Ltd trades at 36.5× P/E, at the pricey end of its own range (94th percentile). Its long-run median P/E is 27.1×, measured across 4.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 36.5× is at the pricey end of its own range (94th percentile), against a long-run median of 27.1× measured over 4.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +11.3% against a +39.2% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +43.5%/yr price move, ~+28.9%/yr came from earnings growth and ~+14.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 28 June 2026 price, Supriya Lifescience Ltd was paying for profit growth of about 20.2% a year. Profit itself has compounded 48.4% a year over the past 9 years. Today the market pays 36.5× P/E, the 94th percentile of its own 5-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 28 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Supriya Lifescience Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 24.3% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +19.0% | +21.6% | +16.2% | — |
| Profit | +11.2% | +32.4% | +11.0% | — |
| EPS | +11.3% | +32.5% | +9.0% | — |
| Share price | +39.2% | +43.5% | — | — |
4-Factor Sector Score
45.3/100 — rank 15 of 24 in Pharma - API & CRAMS · 100% evidence confidence
Supriya Lifescience Ltd scores 45.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 15. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 16.1 + 17.1 + 6.9 + 5.2 = 45.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Supriya Lifescience Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
ATS Volume Timing Reframed · 14 August 2026. In February 2026, management stated that it expected to fully achieve 250 to 300 tons in FY27. In August 2026, management said the 250-ton figure represented a two-year outcome and explicitly stated that it had not guided to that volume for FY27, materially changing the near-term volume assumption without reconciling the prior statement.
🚨 Contrast Media Timeline Deferred · 28 May 2026. In the November 2025 and February 2026 calls, management indicated the contrast media product would be launched in the fourth quarter of FY26. However, in the May 2026 call, they pushed this launch out to the second half of FY27 to perform further R&D on process optimization.
Cardiovascular Intermediate Volume Target Contradicted · 28 May 2026. In the February 2026 call, management explicitly confirmed that the entire 250 to 300 metric tons of cardiovascular intermediate demand would be fully realized in FY27. However, in the May 2026 call, they changed this position, stating that these volumes will not come fully in FY27 and will instead manifest over the next two to three years.
Protein Project Revenue Forecast Cut · 28 May 2026. In the November 2025 call, management expected the Whey Protein contract to scale quickly and generate the majority of its potential revenue in FY27. However, in the May 2026 call, they stated that they do not see any large revenues coming from this project in FY27 as formulation development continues.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Neuland Laboratories LtdNEULANDLAB | 81.2/100Sector-leading setup100% evidence | LEADER | 33.6/35 Revenue 78.3% · PAT 100% · OPM change 23 pp 100% evidence | 19.9/25 ROCE 26.5% · OPM 35% 100% evidence | 12.0/20 P/E 60.7× · PEG 1.05 100% evidence | 15.7/20 RS sector 7.5% · RS bench 44.6% · 1Y 62.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 33.6 + 19.9 + 12 + 15.7 = 81.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Acutaas Chemicals LtdACUTAAS | 77.3/100Favorable setup76% evidence | 31.9/35 Revenue 41% · PAT 100% · OPM change 9 pp 95% evidence | 20.1/25 ROCE 31.6% · OPM 34% 76% evidence | 9.3/20 P/E 71.7× · PEG — 50% evidence | 16.0/20 RS sector 86.5% · RS bench 43.7% · 1Y 129.5%5 of 8 weeks ahead 70% evidence | |
| Exact sum: 31.9 + 20.1 + 9.3 + 16 = 77.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3IOL Chemicals & Pharmaceuticals LtdIOLCP | 73.0/100Favorable setup100% evidence | LEADER | 28.5/35 Revenue 18.5% · PAT 60% · OPM change 3 pp 100% evidence | 12.5/25 ROCE 11.3% · OPM 14% 100% evidence | 13.8/20 P/E 32.3× · PEG 0.66 100% evidence | 18.2/20 RS sector 37.2% · RS bench 81.2% · 1Y 100.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 12.5 + 13.8 + 18.2 = 73 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Laurus Labs LtdLAURUSLABS | 71.2/100Favorable setup93% evidence | LEADER | 32.2/35 Revenue 22.6% · PAT 100% · OPM change 8 pp 100% evidence | 18.2/25 ROCE 17.8% · OPM 32% 100% evidence | 5.3/20 P/E 97.3× · PEG 3.33 65% evidence | 15.5/20 RS sector 22.2% · RS bench 63.4% · 1Y 123.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 18.2 + 5.3 + 15.5 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Gland Pharma LtdGLAND | 69.7/100Favorable setup100% evidence | LEADER | 26.4/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 27% 100% evidence | 14.2/20 P/E 42.1× · PEG 1.45 100% evidence | 15.2/20 RS sector 8.2% · RS bench 45.5% · 1Y 54.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.9 + 14.2 + 15.2 = 69.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Divis Laboratories LtdDIVISLAB | 65.4/100Favorable setup100% evidence | LEADER | 26.5/35 Revenue 16.4% · PAT 26.8% · OPM change 11 pp 100% evidence | 19.1/25 ROCE 22% · OPM 41% 100% evidence | 3.5/20 P/E 83.1× · PEG 3.45 100% evidence | 16.3/20 RS sector 3.2% · RS bench 39.9% · 1Y 55.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 19.1 + 3.5 + 16.3 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Shilpa Medicare LtdSHILPAMED | 63.1/100Mixed-positive evidence100% evidence | LEADER | 27.6/35 Revenue 28% · PAT 100% · OPM change 1 pp 100% evidence | 10.3/25 ROCE 10.9% · OPM 29% 100% evidence | 5.6/20 P/E 66.1× · PEG 6.86 100% evidence | 19.6/20 RS sector 60.8% · RS bench 111.5% · 1Y 127.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.6 + 10.3 + 5.6 + 19.6 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sai Life Sciences LtdSAILIFE | 62.9/100Mixed-positive evidence93% evidence | LEADER | 27.2/35 Revenue 17.6% · PAT 48% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.6% · OPM 27% 100% evidence | 4.9/20 P/E 91.6× · PEG 3.46 65% evidence | 14.2/20 RS sector 12.7% · RS bench 51.7% · 1Y 84.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 16.6 + 4.9 + 14.2 = 62.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 9Granules India LtdGRANULES | 62.4/100Mixed-positive evidence100% evidence | LEADER | 26.4/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.8/25 ROCE 15.5% · OPM 23% 100% evidence | 10.4/20 P/E 34.7× · PEG 1.27 100% evidence | 9.8/20 RS sector 1.7% · RS bench 37.1% · 1Y 77.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 15.8 + 10.4 + 9.8 = 62.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Windlas Biotech LtdWINDLAS | 53.5/100Mixed-positive evidence77% evidence | BREAKING OUT | 16.7/35 Revenue 18.8% · PAT 9.8% · OPM change -2 pp 83% evidence | 14.5/25 ROCE 15.9% · OPM 11% 95% evidence | 11.5/20 P/E 35.1× · PEG — 50% evidence | 10.8/20 RS sector -1.8% · RS bench 34.7% · 1Y 13.7%5 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.5 + 11.5 + 10.8 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Anthem Biosciences LtdANTHEM | 53.0/100Mixed-positive evidence77% evidence | BREAKING OUT | 12.7/35 Revenue -2.1% · PAT 14.1% · OPM change 1 pp 100% evidence | 22.0/25 ROCE 30.4% · OPM 36% 100% evidence | 9.2/20 P/E 89.3× · PEG — 15% evidence | 9.1/20 RS sector -4.6% · RS bench 29.4% · 1Y 13.4%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.7 + 22 + 9.2 + 9.1 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12SMS Pharmaceuticals LtdSMSPHARMA | 48.7/100Mixed-negative evidence100% evidence | TURNING | 19.1/35 Revenue 10.2% · PAT 41.7% · OPM change 0 pp 100% evidence | 11.3/25 ROCE 13.3% · OPM 20% 100% evidence | 10.3/20 P/E 42.4× · PEG 1.53 100% evidence | 8.0/20 RS sector -2.8% · RS bench 32.7% · 1Y 96.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 11.3 + 10.3 + 8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Morepen Laboratories LtdMOREPENLAB | 48.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.3/35 Revenue 9.5% · PAT 51.6% · OPM change 8 pp 100% evidence | 8.5/25 ROCE 8.1% · OPM 14% 100% evidence | 9.7/20 P/E 54× · PEG 1.68 100% evidence | 10.0/20 RS sector -16.2% · RS bench 130.1% · 1Y 134.8%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 8.5 + 9.7 + 10 = 48.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Blue Jet Healthcare LtdBLUEJET | 46.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 5.8/35 Revenue -27.5% · PAT -34.6% · OPM change -1 pp 100% evidence | 21.0/25 ROCE 26.1% · OPM 33% 100% evidence | 13.8/20 P/E 45.8× · PEG 1.39 100% evidence | 5.9/20 RS sector -39.2% · RS bench 12% · 1Y -23.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 5.8 + 21 + 13.8 + 5.9 = 46.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Supriya Lifescience Ltdthis pageSUPRIYA | 45.3/100Mixed-negative evidence100% evidence | FADING | 16.1/35 Revenue 28.2% · PAT 11.2% · OPM change -11 pp 100% evidence | 17.1/25 ROCE 25.2% · OPM 25% 100% evidence | 6.9/20 P/E 36.5× · PEG 3.11 100% evidence | 5.2/20 RS sector -11.2% · RS bench 20.4% · 1Y 38.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 17.1 + 6.9 + 5.2 = 45.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Concord Biotech LtdCONCORDBIO | 37.8/100Mixed-negative evidence94% evidence | BREAKING OUT | 9.2/35 Revenue -6.7% · PAT -23.3% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 17.1% · OPM 32% 100% evidence | 6.7/20 P/E 56.7× · PEG 5.67 100% evidence | 7.0/20 RS sector -23.6% · RS bench 16.4% · 1Y -9.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.2 + 14.9 + 6.7 + 7 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Jubilant Pharmova LtdJUBLPHARMA | 37.6/100Mixed-negative evidence93% evidence | TURNING | 11.8/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 6.8/25 ROCE 9% · OPM 11% 100% evidence | 13.9/20 P/E 42.1× · PEG 1.17 65% evidence | 5.1/20 RS sector -23% · RS bench 5.6% · 1Y -4.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 6.8 + 13.9 + 5.1 = 37.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Piramal Pharma LtdPPLPHARMA | 35.2/100Mixed-negative evidence71% evidence | LEADER | 13.0/35 Revenue 0.8% · PAT -80% · OPM change 3 pp 74% evidence | 1.4/25 ROCE 2.5% · OPM 9% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.8/20 RS sector -10.9% · RS bench 21.1% · 1Y 5.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 1.4 + 10 + 10.8 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Solara Active Pharma Sciences LtdSOLARA | 34.7/100Adverse evidence83% evidence | TURNING | 7.9/35 Revenue 15.6% · PAT -80% · OPM change -2 pp 100% evidence | 3.8/25 ROCE 4.9% · OPM 16% 100% evidence | 8.5/20 P/E 843× · PEG — 15% evidence | 14.5/20 RS sector 1.9% · RS bench 38.7% · 1Y 12.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 3.8 + 8.5 + 14.5 = 34.7 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Hikal LtdHIKAL | 33.0/100Adverse evidence81% evidence | BREAKING OUT | 11.6/35 Revenue -5.4% · PAT -80% · OPM change 2.6 pp 74% evidence | 4.3/25 ROCE 3.5% · OPM 9.2% 100% evidence | 7.4/20 P/E 65.4× · PEG — 50% evidence | 9.7/20 RS sector -21.7% · RS bench 6.9% · 1Y -14.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 4.3 + 7.4 + 9.7 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21OneSource Specialty Pharma LtdONESOURCE | 27.5/100Adverse evidence71% evidence | BASING | 11.3/35 Revenue 4.3% · PAT -80% · OPM change 0 pp 74% evidence | 3.3/25 ROCE 0.6% · OPM 27% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -27.3% · RS bench -0.8% · 1Y -15%3 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 3.3 + 10 + 2.9 = 27.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Syngene International LtdSYNGENE | 23.6/100Adverse evidence100% evidence | BASING | 6.7/35 Revenue -3.4% · PAT -56.4% · OPM change -11.3 pp 100% evidence | 8.6/25 ROCE 10% · OPM 12.3% 100% evidence | 8.1/20 P/E 52.2× · PEG 7.87 100% evidence | 0.2/20 RS sector -44.2% · RS bench -22.8% · 1Y -41%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.7 + 8.6 + 8.1 + 0.2 = 23.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Dishman Carbogen Amcis LtdDCAL | 22.1/100Adverse evidence87% evidence | ASLEEP | 7.0/35 Revenue 0.2% · PAT -80% · OPM change -11 pp 100% evidence | 4.8/25 ROCE 3.1% · OPM 9% 100% evidence | 6.4/20 P/E 145× · PEG 2.65 65% evidence | 3.9/20 RS sector -31% · RS bench -18.6% · 1Y -39.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 7 + 4.8 + 6.4 + 3.9 = 22.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Cohance Lifesciences LtdCOHANCE | 20.6/100Adverse evidence82% evidence | BREAKING OUT | 3.0/35 Revenue -19.8% · PAT -80% · OPM change -19.7 pp 95% evidence | 6.8/25 ROCE 5.8% · OPM 0.3% 76% evidence | 5.5/20 P/E 156× · PEG — 50% evidence | 5.3/20 RS sector -33.4% · RS bench -9.2% · 1Y -52.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 6.8 + 5.5 + 5.3 = 20.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Supriya Lifescience Ltd's share price today?
Supriya Lifescience Ltd trades at ₹902, +39.2% over the past year. The company is valued at ₹7,258 Cr. The stock sits at 75% of its 52-week range of ₹577–₹1,009, +15.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 15 weeks in. — as of 11 September 2026.
What were Supriya Lifescience Ltd's latest quarterly results?
Supriya Lifescience Ltd reported revenue of ₹190 Cr and net profit of ₹24.0 Cr for the Jun 26 quarter. Revenue rose 31.0% and profit fell 31.4% year on year. Earnings per share were ₹2.99. The operating margin was 25.0%, 11.0 pp lower than a year earlier. — as of 11 September 2026.
What is Supriya Lifescience Ltd's revenue?
Supriya Lifescience Ltd reported revenue of ₹190 Cr in the Jun 26 quarter, +31.0% year on year. For the full FY26 fiscal year, revenue was ₹828 Cr (+19.0%). Over the last 9 years revenue compounded at 18.2% a year. — as of 11 September 2026.
What is Supriya Lifescience Ltd's profit?
Supriya Lifescience Ltd earned ₹24.0 Cr of net profit in the Jun 26 quarter, −31.4% year on year. Full-year FY26 profit was ₹209 Cr. The operating margin ran 25.0% in the latest quarter. — as of 11 September 2026.
What is Supriya Lifescience Ltd's market cap?
Supriya Lifescience Ltd's market capitalisation is ₹7,258 Cr at a share price of ₹902. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Supriya Lifescience Ltd's P/E ratio?
Supriya Lifescience Ltd trades at a P/E of 36.5×, at the 94th percentile of its own 5-year range, against a long-run median of 27.1×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Supriya Lifescience Ltd pay a dividend?
Yes — Supriya Lifescience Ltd's dividend payout was 4% of profit in FY26, and it recorded a payout in 7 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Supriya Lifescience Ltd overvalued?
On its own history, Supriya Lifescience Ltd looks expensive: its P/E of 36.5× sits at the 94th percentile of its 5-year range (long-run median 27.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Supriya Lifescience Ltd growing?
Not right now — Supriya Lifescience Ltd's latest numbers are shrinking: latest-quarter revenue +31.0% year on year, profit −31.4%, and the margin −11.0 pp at 25.0%. The 9-year compound rates are 18.2% (revenue) and 48.4% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is Supriya Lifescience Ltd performing?
Supriya Lifescience Ltd is in a confirmed uptrend, 15 weeks in. Its latest quarter's revenue rose 31.0% and profit fell 31.4% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Supriya Lifescience Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 24.3% and holding. The read comes from the last 12 quarters of growth (revenue growth +28.2% latest, profit growth +11.2% latest, eps growth +11.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Supriya Lifescience Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 15 of stage 2), trading +15.0% versus its 200-day average and at 75% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Supriya Lifescience Ltd beating the market?
Not lately — on a trailing-13-week view Supriya Lifescience Ltd is currently behind the NIFTY 500 (9 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4.7 years the stock moved +86% against the NIFTY 500's +49% — ahead of the index over the full window. — as of 11 September 2026.
Will Supriya Lifescience Ltd's share price go up?
This page publishes no price forecast for Supriya Lifescience Ltd. What it measures instead: the share price is ₹902, the price is in a confirmed uptrend 15 weeks in. Its P/E of 36.5× sits at the 94th percentile of its own 5-year range. — as of 11 September 2026.
Who owns Supriya Lifescience Ltd?
Promoters hold 68.3% of Supriya Lifescience Ltd, foreign institutions 6.2%, domestic institutions 5.3% and the public 20.2% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 1.2 points over 8 quarters. — as of 11 September 2026.
Does Supriya Lifescience Ltd have too much debt?
No — Supriya Lifescience Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 98×. FY26 borrowings were ₹5.0 Cr against equity of ₹1,198 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Supriya Lifescience Ltd's capex?
Supriya Lifescience Ltd spent ₹459 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹152 Cr, with ₹36.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Supriya Lifescience Ltd's cash flow?
Supriya Lifescience Ltd generated ₹186 Cr of operating cash flow in FY26 and ₹34.0 Cr of free cash flow after ₹152 Cr of capital spending. Reported profit that year was ₹209 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Supriya Lifescience Ltd's profit real cash?
Yes — over the last 3 fiscal years, 90% of Supriya Lifescience Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹186 Cr against reported profit of ₹209 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Supriya Lifescience Ltd in its business cycle?
Supriya Lifescience Ltd's FY26 operating margin was 36.0%, against a 10-year band of 9.0%–44.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 25.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Supriya Lifescience Ltd's price assume?
At its price on 28 June 2026, Supriya Lifescience Ltd was priced for profit growth of about 20.2% a year. Profit itself has compounded 48.4% a year over the past 9 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Supriya Lifescience Ltd story?
The sharpest disagreement: the price moved +39.2% in a year while annual EPS moved +11.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Supriya Lifescience Ltd a stock worth studying right now?
This is not investment advice. The machine read: Supriya Lifescience Ltd's price has outrun its earnings. +39.2% in a year against EPS +11.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!